“ In 2006, bioXXmed AG was founded – as CytoTools AG - in Darmstadt (Germany). The company is listed at the Frankfurt Exchange (Basic Board) and acts as equity investor in biotech companies by continuous increase of its own share capital. About 48% of the shares are held by two main investors, the majority of the shares are free float.
bioXXmed AG has invested more than 22 Mil. € in several development projects of two holding companies. They pursued pre-clinical and clinical projects in oncology, cardiovascular, sepsis and dermatology. The newly appointed management of bioXXmed AG (September 2021) commissioned a thorough analysis of the entire project portfolio in its investments. As a result of this analysis, bioXXmed decided to focus strategically primarily on investments in Dermatology. This clinical segment offers a lot of unmet medical needs. Primary or secondary skin diseases are sometimes symptomatically treatable, but often not curable.
Moreover, the most advanced, near-market product DermaPro® in one of the holding companies, is indicated for the treatment of chronic wounds, in particular the diabetic foot syndrome. The chemical product DermaPro® is applied topically, and has shown safety and efficacy in several clinical trials by reducing or healing ulcers in diabetes. This indication is an unsolved medical problem with a prevalence of at least 6% among diabetic patients. Secondary complications as amputations are serious and the cost burden for healthcare systems is extreme.
The product is under final development to be licensed as medicinal product in Europe (CE registration), probably towards the end of next year.
bioXXmed is currently evaluating some very promising new projects in Dermatology which would support the bioXXmed focus on Dermatology in very relevant disease indications. bioXXmed AG has a competent team which is up to the successful management of dermatological projects. Hence, bioXXmed AG will provide development and commercial know-how to the project partner and take an active role in managing such projects.
We are interested in a broader and more international base of financial investors to accelerate the development of such projects and thereby to enhance the value of bioXXmed AG for our shareholders”.
Categories: Member News